 |
PDBsum entry 2ypl
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Immune system/viral protein
|
PDB id
|
|
|
|
2ypl
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
274 a.a.
|
 |
|
|
|
|
|
|
|
99 a.a.
|
 |
|
|
|
|
|
|
|
11 a.a.
|
 |
|
|
|
|
|
|
|
199 a.a.
|
 |
|
|
|
|
|
|
|
238 a.a.
|
 |
|
|
|
|
|
|
|
|
|
PDB id:
|
 |
|
 |
| Name: |
 |
Immune system/viral protein
|
 |
|
Title:
|
 |
Structural features underlying t-cell receptor sensitivity to concealed mhc class i micropolymorphisms
|
|
Structure:
|
 |
Hla class i histocompatibility antigen, b-57 alpha chain. Chain: a. Fragment: residues 25-298. Synonym: bw-57, mhc class i antigen b 57, Hla-b5703. Engineered: yes. Beta-2-microglobulin. Chain: b. Synonym: beta-2-microglobulin form pi 5.3. Engineered: yes.
|
|
Source:
|
 |
Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562. Synthetic: yes. Human immunodeficiency virus. Organism_taxid: 12721.
|
|
Resolution:
|
 |
|
2.40Å
|
R-factor:
|
0.224
|
R-free:
|
0.277
|
|
|
Authors:
|
 |
G.B.Stewart-Jones,P.Simpson,P.A.Van Der Merwe,P.Easterbrook, A.J.Mcmichael,S.L.Rowland-Jones,E.Y.Jones,G.M.Gillespie
|
|
Key ref:
|
 |
G.B.Stewart-Jones
et al.
(2012).
Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms.
Proc Natl Acad Sci U S A,
109,
E3483.
PubMed id:
|
 |
|
Date:
|
 |
|
30-Oct-12
|
Release date:
|
28-Nov-12
|
|
|
|
|
|
PROCHECK
|
|
|
|
|
Headers
|
 |
|
|
References
|
|
|
|
|
|
|
P01889
(1B07_HUMAN) -
HLA class I histocompatibility antigen, B alpha chain from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
362 a.a.
274 a.a.*
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
P61769
(B2MG_HUMAN) -
Beta-2-microglobulin from Homo sapiens
|
|
|
|
Seq: Struc:
|
 |
 |
 |
119 a.a.
99 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
|
|
|
Q70XD7
(Q70XD7_HV1) -
Gag polyprotein from Human immunodeficiency virus type 1
|
|
|
|
Seq: Struc:
|
 |
 |
 |
1499 a.a.
11 a.a.
|
|
|
|
|
|
|
|
|
 |
 |
|
 |
|
|
 |
 |
 |
 |
Enzyme class 2:
|
 |
Chain C:
E.C.3.1.13.2
- exoribonuclease H.
|
|
 |
 |
 |
 |
 |
Reaction:
|
 |
Exonucleolytic cleavage to 5'-phosphomonoester oligonucleotides in both 5'- to 3'- and 3'- to 5'-directions.
|
 |
 |
 |
 |
 |
Enzyme class 3:
|
 |
Chain C:
E.C.3.1.26.13
- retroviral ribonuclease H.
|
|
 |
 |
 |
 |
 |
 |
 |
|
Note, where more than one E.C. class is given (as above), each may
correspond to a different protein domain or, in the case of polyprotein
precursors, to a different mature protein.
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
| |
|
|
Proc Natl Acad Sci U S A
109:E3483
(2012)
|
|
PubMed id:
|
|
|
|
|
| |
|
Structural features underlying T-cell receptor sensitivity to concealed MHC class I micropolymorphisms.
|
|
G.B.Stewart-Jones,
P.Simpson,
P.A.van der Merwe,
P.Easterbrook,
A.J.McMichael,
S.L.Rowland-Jones,
E.Y.Jones,
G.M.Gillespie.
|
|
|
|
| |
ABSTRACT
|
|
|
| |
|
Polymorphic differences distinguishing MHC class I subtypes often permit the
presentation of shared epitopes in conformationally identical formats but can
affect T-cell repertoire selection, differentially impacting autoimmune
susceptibilities and viral clearance in vivo. The molecular mechanisms
underlying this effect are not well understood. We performed structural,
thermodynamic, and functional analyses of a conserved T-cell receptor (TCR)
which is frequently expanded in response to a HIV-1 epitope when presented by
HLA-B*5701 but is not selected by HLA-B*5703, which differs from HLA-B*5701 by
two concealed polymorphisms. Our findings illustrate that although both HLA-B*57
subtypes display the epitope in structurally conserved formats, the impact of
their polymorphic differences occurs directly as a consequence of TCR ligation,
primarily because of peptide adjustments required for TCR binding, which
involves the interplay of polymorphic residues and water molecules. These minor
differences culminate in subtype-specific differential TCR-binding kinetics and
cellular function. Our data demonstrate a potential mechanism whereby the most
subtle MHC class I micropolymorphisms can influence TCR use and highlight their
implications for disease outcomes.
|
|
|
|
|
|
|
 |
 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
');
}
}
| | |